医学
化学免疫疗法
淋巴瘤
嵌合抗原受体
滤泡性淋巴瘤
弥漫性大B细胞淋巴瘤
肿瘤科
免疫学
内科学
癌症研究
美罗华
癌症
免疫疗法
作者
Julio C. Chávez,Frederick L. Locke
标识
DOI:10.1016/j.beha.2018.04.001
摘要
B-cell non-Hodgkin's lymphoma (NHLs)is a very heterogonous malignancy with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) as the most common subtypes. Standard treatment with anti-CD20 based chemoimmunotherapy is usually very effective for disease control. However a significant proportion of patients with high-risk features (double hit lymphoma, transformed lymphomas or early relapses) will become refractory to standard therapies and will have limited alternatives for cure. Adoptive therapy with chimeric antigen receptor (CAR) T-cells is a new paradigm for effective treatment of poor prognosis lymphomas. Here we review the biology of poor risk DLBCL and FL, the rationale for CAR T-cell therapy in malignant lymphoma and the efficacy/toxicity profile of CD19 directed CAR T cell therapy for DLBCL and FL from early single center studies to multicenter/global clinical trial with different CAR T cell constructs.
科研通智能强力驱动
Strongly Powered by AbleSci AI